ALERS Eurobio-Scientific SA

2019 FINANCIAL COMMUNICATION CALENDAR

2019 FINANCIAL COMMUNICATION CALENDAR

2019 FINANCIAL COMMUNICATION CALENDAR

Paris, January 8, 2019 – 5.45 pm

Eurobio Scientific (FR0013240934, ALERS, eligible PEA-PME), leading French group in the field of specialty in vitro medical diagnostics, announces its financial communication calendar for the next year:

  • 2018 Turnover: January 29, 2019
  • 2018 Annual results: April 16, 2019
  • Annual Shareholders meeting: June 25, 2019
  • 2019 Half-year turnover: July 23, 2019
  • 2019 Half-year results: October 15, 2019

Calendar may be subject to change and is communicated on an indicative basis.

Upcoming financial meeting

2018 Turnover: January 29, 2019

About Eurobio Scientific



Eurobio Scientific (ex Diaxonhit) is a key player in the field of specialty in vitro diagnostics. It is involved from research to manufacturing and commercialization of diagnostic tests in the fields of transplantation, immunology and infectious diseases, and sells instruments and products for research laboratories, including biotechnology and pharmaceutical companies. Through many partnerships and a strong presence in hospitals, Eurobio Scientific has established its own distribution network and a portfolio of proprietary products in the molecular biology field. The Group has approximately 120 employees and two production units based in the Paris region and in the United States.



 



For more information, please visit:



 



The company is publicly listed on the Euronext Growth market in Paris



Euronext Growth BPI Innovation, PEA-PME 150 and Next Biotech indices.



Symbol : ALERS - ISIN Code: FR0013240934  -  Reuters : ALERS.PA  - Bloomberg : ALERS:FP



 



 
Contacts



Eurobio Scientific Group



Denis Fortier, General Manager



Hervé Duchesne de Lamotte, General Manager



Tel. 80



 
Calyptus



Sophie Levesque / Mathieu Calleux



Investor Relations



Tel. 68 -

Attachment

EN
08/01/2019

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Eurobio-Scientific SA

 PRESS RELEASE

Eurobio Scientific: 2025 FY revenue

Eurobio Scientific: 2025 FY revenue FISCAL YEAR 2025, CONFIRMATION OF STRATEGIC TRANSFORMATION 9% increase in annual revenue to €168 millionDeployment of the Group's strategy: Proprietary products: 35% of revenueInternationalization: 42% of revenue generated outside France Strengthening of activities in Italy with the acquisition of Quimark and the assets of the Life Sciences unit of Voden Medical Instruments Spa Paris, January 27, 2026 - 5:40 p.m. - Eurobio Scientific (FR0013240934, ALERS), a leading French group in in vitro medical diagnostics and life sciences today presents its cons...

 PRESS RELEASE

Eurobio Scientific : chiffre d'affaires 2025

Eurobio Scientific : chiffre d'affaires 2025 EXERCICE 2025, CONFIRMATION DE LA TRANSFORMATION STRATEGIQUE Progression du chiffre d’affaires annuel de 9% à 168 M€Déploiement de la stratégie du Groupe : Produits propriétaires : 35% du Chiffre d’affairesInternationalisation : 42% du Chiffre d’affaires réalisé hors de France  Renforcement des activités en Italie avec l’acquisition de Quimark et des actifs de l'unité Sciences de la vie de Voden Medical Instruments Spa Paris, le 27 janvier 2026 – 17h45 Eurobio Scientific (FR0013240934, ALERS, éligible PEA-PME), groupe français leader dans le...

 PRESS RELEASE

EUROBIO SCIENTIFIC: REPLACEMENT OF A STATUTORY AUDITOR

EUROBIO SCIENTIFIC: REPLACEMENT OF A STATUTORY AUDITOR REPLACEMENT OF A STATUTORY AUDITOR Paris, December 22, 2025 – 6:00 pm Eurobio Scientific (FR0013240934, ALERS), a leading French group in in vitro medical diagnostics and life sciences, announces the replacement of one of its statutory auditors, Endrix LYO, by RSM France, which was selected following a competitive selection process This replacement follows the resignation of Endrix LYO on December 18, 2025, motivated by the acquisition of a stake in its capital by IK Partners 1, which is also an indirect shareholder of Eurobio Scient...

 PRESS RELEASE

EUROBIO SCIENTIFIC : REMPLACEMENT D’UN COMMISSAIRE AUX COMPTES

EUROBIO SCIENTIFIC : REMPLACEMENT D’UN COMMISSAIRE AUX COMPTES REMPLACEMENT D’UN COMMISSAIRE AUX COMPTES Paris, le 22 décembre 2025 – 18h00 Eurobio Scientific (FR0013240934, ALERS, éligible PEA-PME), groupe français leader dans le diagnostic médical in vitro de spécialité, annonce le remplacement d’un de ses commissaires aux comptes titulaires, Endrix LYO, par le cabinet RSM France qui a été choisi à l’issue d’un processus de sélection compétitif. Ce remplacement fait suite à la démission intervenue le 18 décembre 2025 d’Endrix LYO, motivée par l’entrée à son capital d’IK Partners 1, par...

 PRESS RELEASE

EUROBIO SCIENTIFIC : MISE À DISPOSITION DU RAPPORT FINANCIER SEMESTRIE...

EUROBIO SCIENTIFIC : MISE À DISPOSITION DU RAPPORT FINANCIER SEMESTRIEL 2025 MISE À DISPOSITION DU RAPPORT FINANCIER SEMESTRIEL 2025 Paris, le 13 octobre 2025 – 18h30 Eurobio Scientific (FR0013240934, ALERS, éligible PEA-PME), groupe français leader dans le diagnostic médical in vitro de spécialité, annonce avoir mis à disposition du public et déposé auprès de l’Autorité des Marchés Financiers (AMF) le 13 octobre 2025 son rapport financier semestriel au 30 juin 2025. Le rapport financier annuel peut être consulté sur le site Internet de la société à l’adresse : dans la rubrique « Invest...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch